Works about CYTOCHROME P-450 CYP3A

Results: 729

Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies.

Published in:

Clinical Pharmacology in Drug Development, 2025, v. 14, n. 7, p. 520, doi. 10.1002/cpdd.1543

By:

Chen, Yingxue;
Teng, Renli;
Szanto, Attila;
Kapopara, Apoorva;
Bannerji, Rajat;
Ogier, Julien;
Mahalingam, Devalingam

Publication type:

Article

First‐in‐Human Phase 1 Study to Evaluate the Clinical Pharmacology Properties of RBN‐3143, a Novel Inhibitor of Mono‐Adenosine Diphosphate Ribosyltransferase‐PARP14.

Published in:

Clinical Pharmacology in Drug Development, 2025, v. 14, n. 7, p. 493, doi. 10.1002/cpdd.1539

By:

Polasek, Thomas M.;
Cole, Alexandra;
Bozón, Viviana;
Manyak, Erika;
Novak, Jonathan;
Yang, Barbara;
Johnston, Briohny A.;
Parasuraman, Sudha;
Paneliya, Kushal J.;
Schuck, Virna

Publication type:

Article

Development of a Novel CYP3A4 Classifier Model via Site of Metabolism (SOM)-based Molecular Docking, Multivariate Analysis and Molecular Dynamics of Known Substrates and Inhibitors.

Published in:

Journal of Computational Biophysics & Chemistry, 2024, v. 23, n. 2, p. 243, doi. 10.1142/S2737416523500618

By:

Mohamad Ridhwan, Mohamad Jemain;
Hashim, Nurul Azmir Amir;
Kasim, Noraini;
Abdullah, Nor Nadirah;
Inayatsyah, Nurul Alam;
Abid, Obaidurahman;
Ismail, Nor Hadiani;
Imran, Syahrul

Publication type:

Article

A Comprehensive Analysis of Human CYP3A4 Crystal Structures as a Potential Tool for Molecular Docking-Based Site of Metabolism and Enzyme Inhibition Studies.

Published in:

Journal of Computational Biophysics & Chemistry, 2022, v. 21, n. 3, p. 259, doi. 10.1142/S2737416522300012

By:

Ridhwan, Mohamad Jemain Mohamad;
Bakar, Syahrul Imran Abu;
Latip, Normala Abd;
Ghani, Nurunajah Ab;
Ismail, Nor Hadiani

Publication type:

Article

金鸡菊苷与 CYP3A4/CYP2D6 的结合特性和稳定性.

Published in:

Journal of Jilin University (Science Edition) / Jilin Daxue Xuebao (Lixue Ban), 2024, v. 62, n. 6, p. 1491, doi. 10.13413/j.cnki.jdxblxb.2024185

By:

李丽;
李媛;
陶彦舟;
廉笛;
崔晶晶;
杜雨桐

Publication type:

Article

Single Nucleotide Polymorphisms of CYP3A4 and CYP3A5 in Romanian Kidney Transplant Recipients: Effect on Tacrolimus Pharmacokinetics in a Single-Center Experience.

Published in:

Journal of Clinical Medicine, 2024, v. 13, n. 7, p. 1968, doi. 10.3390/jcm13071968

By:

Rotarescu, Corina Andreea;
Maruntelu, Ion;
Rotarescu, Ion;
Constantinescu, Alexandra-Elena;
Constantinescu, Ileana

Publication type:

Article

Comparison of Tacrolimus Intra-Patient Variability during 6–12 Months after Kidney Transplantation between CYP3A5 Expressers and Nonexpressers.

Published in:

Journal of Clinical Medicine, 2022, v. 11, n. 21, p. 6320, doi. 10.3390/jcm11216320

By:

Nuchjumroon, Almas;
Vadcharavivad, Somratai;
Singhan, Wanchana;
Poosoonthornsri, Manorom;
Chancharoenthana, Wiwat;
Udomkarnjananun, Suwasin;
Townamchai, Natavudh;
Avihingsanon, Yingyos;
Praditpornsilpa, Kearkiat;
Eiam-Ong, Somchai

Publication type:

Article

Metabolic Profiling and Investigation of the Modulatory Effect of Fagonia cretica L. Aerial Parts on Hepatic CYP3A4 and UGT2B7 Enzymes in Streptozotocin—Induced Diabetic Model.

Published in:

Antioxidants, 2023, v. 12, n. 1, p. 119, doi. 10.3390/antiox12010119

By:

Kamran, Shahzad;
Anwar, Rukhsana;
Noor, Afifa;
Ullah, Muhammad Ihsan;
Bagalagel, Alaa A.;
Aldurdunji, Mohammed M.;
Ishtiaq, Saiqa

Publication type:

Article

Tacrolimus Concentration Is Effectively Predicted Using Combined Clinical and Genetic Factors in the Perioperative Period of Kidney Transplantation and Associated with Acute Rejection.

Published in:

2022

By:

Cheng, Fang;
Li, Qiang;
Cui, Zheng;
Wang, Zhendi;
Zeng, Fang;
Zhang, Yu

Publication type:

journal article

Neratinib causes non-recoverable gut injury and reduces intestinal cytochrome P450 3A enzyme in mice.

Published in:

Toxicology Research, 2022, v. 11, n. 1, p. 184, doi. 10.1093/toxres/tfab111

By:

Tao, Gabriel;
Dagher, Fatima;
Ghose, Romi

Publication type:

Article

A systematic review of the drug-drug interaction between Statins and Quinolones.

Published in:

BMC Pharmacology & Toxicology, 2024, v. 25, n. 1, p. 1, doi. 10.1186/s40360-024-00760-8

By:

Zhou, Jifang;
Yu, Lixia;
Xu, Huimin

Publication type:

Article

Prediction of drug–drug interactions between roflumilast and CYP3A4/1A2 perpetrators using a physiologically-based pharmacokinetic (PBPK) approach.

Published in:

BMC Pharmacology & Toxicology, 2024, v. 25, n. 1, p. 1, doi. 10.1186/s40360-023-00726-2

By:

Jia, Guangwei;
Ren, Congcong;
Wang, Hongyan;
Fan, Caixia

Publication type:

Article

A Drug–Drug Interaction Study of Mobocertinib and Midazolam, a Cytochrome P450 3A Substrate, in Patients With Advanced Non–Small Cell Lung Cancer.

Published in:

Clinical Pharmacology in Drug Development, 2025, v. 14, n. 3, p. 252, doi. 10.1002/cpdd.1500

By:

Hanley, Michael J.;
Zhang, Steven;
Pavlakis, Nick;
Soo, Ross A.;
van der Wekken, Anthonie J.;
Ganju, Vinod;
Piña, Adela;
Dong, Qi;
Gupta, Neeraj

Publication type:

Article

Effect of Itraconazole, a CYP3A4 Inhibitor, and Rifampin, a CYP3A4 Inducer, on the Pharmacokinetics of Vatiquinone.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 12, p. 1283, doi. 10.1002/cpdd.1461

By:

Lee, Lucy;
Thoolen, Martin;
Ma, Jiyuan;
Kaushik, Diksha;
Golden, Lee;
Kong, Ronald

Publication type:

Article

Absorption, Metabolism, and Excretion of [14C]‐Labeled Anaprazole: A New Proton Pump Inhibitor, After a Single Oral Administration in Healthy Chinese Male Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 10, p. 1115, doi. 10.1002/cpdd.1458

By:

Xie, Lijun;
Xu, Yanjun;
Liu, Wei;
Zhou, Chen;
Guo, Lian;
Zhou, Sufeng;
Zhang, Chen;
Chen, Juan;
Zhu, Bei;
Ding, Sijia;
Li, Huan;
Zhang, Lingling;
Wang, Li;
Xu, Lingmei;
Shao, Feng;
Wang, Lu

Publication type:

Article

Effect of Erdafitinib on the Pharmacokinetics of Midazolam and Metformin in Patients With Advanced Solid Tumors Harboring FGFR Gene Alterations.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 10, p. 1164, doi. 10.1002/cpdd.1445

By:

Zhu, Wei;
Baig, Mahadi;
Naini, Vahid;
De Meulder, Marc;
Akapame, Sydney;
De Zwart, Loeckie;
Haddish‐Berhane, Nahor;
Triantos, Spyros

Publication type:

Article

Clinical Implications of Co‐administering Apixaban with Key Interacting Medications.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 961, doi. 10.1002/cpdd.1446

By:

Favatella, Nicholas;
Dalton, David;
Byon, Wonkyung;
Merali, Samira J.;
Klem, Christian

Publication type:

Article

Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Avacopan, a Small‐Molecule Complement C5a Receptor Antagonist, for the Treatment of Antineutrophil Cytoplasmic Autoantibody‐Associated Vasculitis.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 9, p. 1000, doi. 10.1002/cpdd.1444

By:

Miao, Shichang;
Suso, Pablo;
Furst, John A.;
Hudson, Matthew G.;
Trivedi, Ashit

Publication type:

Article

Effect of Carbamazepine on the Pharmacokinetics of Erdafitinib in Healthy Participants.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 8, p. 852, doi. 10.1002/cpdd.1412

By:

Jaiprasart, Pharavee;
Hellemans, Peter;
Jiao, Juhui James;
Dosne, Anne‐Gaëlle;
De Meulder, Marc;
De Zwart, Loeckie;
Brees, Laurane;
Zhu, Wei

Publication type:

Article

Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 7, p. 810, doi. 10.1002/cpdd.1392

By:

Cardona, Panli;
Dutta, Sandeep;
Houk, Brett

Publication type:

Article

Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug‐Drug Interaction of Avacopan in 2 Open‐Label Studies in Healthy Participants.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 5, p. 517, doi. 10.1002/cpdd.1389

By:

Miao, Shichang;
Bekker, Pirow;
Armas, Danielle;
Lor, Mary;
Han, Yanyan;
Webster, Kenneth;
Trivedi, Ashit

Publication type:

Article

Cedirogant Population Pharmacokinetics and Pharmacodynamic Analyses of Interleukin‐17A Inhibition in Two Phase 1 Studies in Healthy Participants and Participants with Moderate to Severe Psoriasis.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 5, p. 474, doi. 10.1002/cpdd.1377

By:

Maier, Corinna S.;
Eckert, Doerthe;
Laroux, F. Stephen;
Hew, Kinjal M.;
Suleiman, Ahmed A.;
Liu, Wei;
Mohamed, Mohamed‐Eslam F.

Publication type:

Article

Effect of Tacrolimus Formulation (Prolonged‐Release vs Immediate‐Release) on Its Susceptibility to Drug‐Drug Interactions with St. John's Wort.

Published in:

Clinical Pharmacology in Drug Development, 2024, v. 13, n. 3, p. 297, doi. 10.1002/cpdd.1364

By:

Gümüs, Katja S.;
Teegelbekkers, Anna;
Sauter, Max;
Meid, Andreas D.;
Burhenne, Jürgen;
Weiss, Johanna;
Blank, Antje;
Haefeli, Walter E.;
Czock, David

Publication type:

Article

Evaluation of the Cytochrome P450 3A and P‐glycoprotein Drug‐Drug Interaction Potential of Futibatinib.

Published in:

Clinical Pharmacology in Drug Development, 2023, v. 12, n. 10, p. 966, doi. 10.1002/cpdd.1259

By:

Yamamiya, Ikuo;
Hunt, Allen;
Takenaka, Toru;
Sonnichsen, Daryl;
Mina, Mark;
He, Yaohua;
Benhadji, Karim A.;
Gao, Ling

Publication type:

Article

Pharmacokinetics of the Akt Serine/Threonine Protein Kinase Inhibitor, Capivasertib, Administered to Healthy Volunteers in the Presence and Absence of the CYP3A4 Inhibitor Itraconazole.

Published in:

Clinical Pharmacology in Drug Development, 2023, v. 12, n. 9, p. 856, doi. 10.1002/cpdd.1307

By:

Miller, Claire;
Sommavilla, Roberto;
Barry, Simon T.;
Eberlein, Cath;
Morris, Thomas;
Wadsworth, Ian;
Cullberg, Marie

Publication type:

Article

A Phase 1, Open‐Label, Fixed‐Sequence, Drug–Drug Interaction Study of Zanubrutinib with Rifabutin in Healthy Volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2023, v. 12, n. 8, p. 832, doi. 10.1002/cpdd.1250

By:

Tariq, Bilal;
Conto, Stephanie;
Cohen, Aileen;
Sahasranaman, Srikumar;
Ou, Ying C.

Publication type:

Article

Evaluation of Drug–Drug Interaction Potential of Enarodustat (JTZ‐951) Using a Cytochrome P450 Probe Cocktail.

Published in:

Clinical Pharmacology in Drug Development, 2023, v. 12, n. 7, p. 667, doi. 10.1002/cpdd.1263

By:

Pai, Sudhakar M.;
Yamada, Hiroyuki;
Murata, Hiroyuki

Publication type:

Article

Disposition and Mass Balance of Etrasimod in Healthy Subjects and In Vitro Determination of the Enzymes Responsible for Its Oxidative Metabolism.

Published in:

Clinical Pharmacology in Drug Development, 2023, v. 12, n. 6, p. 553, doi. 10.1002/cpdd.1255

By:

Lee, Caroline A.;
Oh, D. Alexander;
Tang, Yong;
Yi, Ping;
Bashir, Mohammad;
English, Stephen;
Croft, Marie;
Blackburn, Anthony;
Bloom, Steve;
Gilder, Kye;
Grundy, John S.

Publication type:

Article

Pharmacokinetic Interaction of Chiglitazar with CYP3A4 Inducer or Inhibitor: An Open‐Label, Sequential Crossover, Self‐Control, 3‐Period Study in Healthy Chinese Volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2023, v. 12, n. 2, p. 168, doi. 10.1002/cpdd.1198

By:

Yuan, Fei;
Li, Jing;
Li, Xuening;
Li, Hui;
Chen, Weili;
Yang, Mengjie;
Chen, Hanjing;
Sheng, Lei;
Liu, Chao;
Wu, Yujia;
Xu, Hongrong

Publication type:

Article

Pharmacokinetics of the Multi‐kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality.

Published in:

Clinical Pharmacology in Drug Development, 2023, v. 12, n. 2, p. 159, doi. 10.1002/cpdd.1186

By:

Zahir, Hamim;
Greenberg, Jonathan;
Hsu, Ching;
Watanabe, Kengo;
Makino, Chie;
He, Ling;
LaCreta, Frank

Publication type:

Article

Drug‐Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ‐56136379 (Bersacapavir).

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 12, p. 1419, doi. 10.1002/cpdd.1164

By:

Vandenbossche, Joris;
Yogaratnam, Jeysen;
Hillewaert, Vera;
Rasschaert, Freya;
Talloen, Willem;
Biewenga, Jeike;
Snoeys, Jan;
Kakuda, Thomas N.;
Palmer, Martyn;
Nangosyah, Julius;
Biermer, Michael

Publication type:

Article

Drug‐Drug Interaction Studies to Evaluate the Effect of Inhibition of UGT1A1 and CYP3A4 and Induction of CYP3A4 on the Pharmacokinetics of Tropifexor in Healthy Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 11, p. 1253, doi. 10.1002/cpdd.1140

By:

Chen, Jin;
Stringer, Rowan;
Shah, Bharti;
Gu, Jessie;
Zhang, Yiming;
Hackling, Melissa;
Prince, William;
Woessner, Ralph

Publication type:

Article

Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 10, p. 1165, doi. 10.1002/cpdd.1110

By:

Li, Xiaoyan;
Shelton, Mark J;
Wang, Jing;
Meade, Julie;
Ruiz‐Soto, Rodrigo

Publication type:

Article

A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 7, p. 795, doi. 10.1002/cpdd.1082

By:

Schueller, Olivier;
Willson, Ashley;
Singh, Nand;
Lohmer, Lauren;
Alabanza, Anginelle;
Patel, Jeegar

Publication type:

Article

A Phase 1, Open‐Label Study to Evaluate the Effect of Food and Concomitant Itraconazole Administration on the Pharmacokinetics of AMG 986 in Healthy Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 7, p. 849, doi. 10.1002/cpdd.1074

By:

Trivedi, Ashit;
Mather, Omar;
Vega, Silvia;
Hutton, Shauna;
Hellawell, Jennifer;
Lee, Edward

Publication type:

Article

Pharmacokinetic Evaluation of the CYP3A4 and CYP2D6 Drug‐Drug Interaction and CYP3A4 Induction Potential of Omecamtiv Mecarbil: Two Open‐Label Studies in Healthy Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 2, p. 185, doi. 10.1002/cpdd.987

By:

Trivedi, Ashit;
Malik, Fady I.;
Jafarinasabian, Pegah;
Zhang, Hanze;
Flach, Stephen;
Abbasi, Siddique;
Dutta, Sandeep;
Lee, Edward

Publication type:

Article

Evaluation of the Pharmacokinetics of Felcisetrag (TAK‐954), a 5‐HT4 Receptor Agonist, in the Presence and Absence of Itraconazole, a Potent CYP3A4 Inhibitor.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 2, p. 142, doi. 10.1002/cpdd.1046

By:

Chen, Chunlin;
Zhang, Liming;
Almansa, Cristina;
Rosario, Maria;
Cwik, Michael;
Balani, Suresh K.;
Lock, Ruth

Publication type:

Article

Effects of Postoperative Day and NR1I2 on Tacrolimus Clearance in Chinese Liver Transplant Recipients—A Population Model Approach.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 11, p. 1385, doi. 10.1002/cpdd.971

By:

Lu, Yanxia;
Xu, Li;
Cui, Jianrong;
Shen, Su;
Li, Xingang

Publication type:

Article

Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 11, p. 1335, doi. 10.1002/cpdd.957

By:

Mohamed, Mohamed‐Eslam F.;
Coppola, Sheryl;
Feng, Tian;
Camp, Heidi S.;
Kim, Elaine;
Othman, Ahmed A.

Publication type:

Article

Human Mass Balance and Metabolite Profiling of [14C]‐Pamiparib, a Poly (ADP‐Ribose) Polymerase Inhibitor, in Patients With Advanced Cancer.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 9, p. 1108, doi. 10.1002/cpdd.943

By:

Mu, Song;
Palmer, Daniel;
Fitzgerald, Richard;
Andreu‐Vieyra, Claudia;
Zhang, Heather;
Tang, Zhiyu;
Su, Dan;
Sahasranaman, Srikumar

Publication type:

Article

Evaluation of the Effects of Repeat‐Dose Dabrafenib on the Single‐Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate).

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 9, p. 1054, doi. 10.1002/cpdd.937

By:

Nebot, Noelia;
Won, Christina S.;
Moreno, Victor;
Muñoz‐Couselo, Eva;
Lee, Dung‐Yang;
Gasal, Eduard;
Bouillaud, Emmanuel

Publication type:

Article

Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 9, p. 1064, doi. 10.1002/cpdd.934

By:

Kharidia, Jahnavi;
Howgate, Eleanor M.;
Laffont, Celine M.;
Liu, Yongzhen;
Young, Malcolm A.

Publication type:

Article

Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 6, p. 681, doi. 10.1002/cpdd.915

By:

Landry, Ishani;
Aluri, Jagadeesh;
Nakai, Kenya;
Hall, Nancy;
Miyajima, Yukiko;
Ueno, Takashi;
Dayal, Satish;
Filippov, Gleb;
Lalovic, Bojan;
Moline, Margaret;
Reyderman, Larisa

Publication type:

Article

Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 2, p. 214, doi. 10.1002/cpdd.723

By:

Tugnait, Meera;
Gupta, Neeraj;
Hanley, Michael J.;
Sonnichsen, Daryl;
Kerstein, David;
Dorer, David J.;
Venkatakrishnan, Karthik;
Narasimhan, Narayana

Publication type:

Article

Recurrent high creatine kinase levels under clozapine treatment - a case report assessing a suspected adverse drug reaction.

Published in:

Frontiers in Psychiatry, 2024, p. 1, doi. 10.3389/fpsyt.2024.1397876

By:

Wiss, Florine M.;
Allemann, Samuel S.;
zu Schwabedissen, Henriette E. Meyer;
Stäuble, Céline K.;
Mikoteit, Thorsten;
Lampert, Markus L.

Publication type:

Article

Chinese population may require further venetoclax dose reduction beyond guidelines when combined with voriconazole: real-world evidence from China.

Published in:

Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1539233

By:

Wang, Rongrong;
Li, Yanfen;
Zhang, Ran;
Ren, Yuan;
Liu, Yifan;
Wang, Tianlin;
Wu, Jin;
Zheng, Xiangjin;
Li, Shu;
Jing, Yu

Publication type:

Article

Impact of CYP3A5 1* and 3* single nucleotide variants on tacrolimus pharmacokinetics and graft rejection risk in pediatric kidney transplant patients.

Published in:

Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1592134

By:

Xajil-Ramos, Lesly Yanira;
Gándara-Mireles, Jesús Alonso;
Vargas Rosales, Rodrigo José;
Sánchez García, Oscar Kevin;
Ruano Toledo, Andrea Mariela;
Aldana de la Cruz, Amy Kateleen;
Lares-Asseff, Ismael;
Patrón-Romero, Leslie;
Almanza-Reyes, Horacio;
Lou-Meda, Randall

Publication type:

Article

Impact of CYP3A4 functional variability on ziprasidone metabolism.

Published in:

Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1585040

By:

Zhou, Qi;
Wu, Yameng;
Ye, Zhize;
Zhang, Zheyan;
Zheng, Kai;
Qian, Jianchang;
Xiao, Zhongxiang;
Lu, Yang

Publication type:

Article

In vivo effects of bempedoic acid on microdosed CYP probe drugs.

Published in:

Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1544956

By:

Stoll, Felicitas;
Amato, Salvatore;
Burhenne, Jürgen;
Blank, Antje

Publication type:

Article

Effect of CYP3A5 genotypes on pharmacokinetic of tacrolimus in colombian liver transplant patients.

Published in:

Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1505490

By:

Lindarte, Erica Fernanda;
De Jesus Vasquez, Gonzalo;
Toro Rendón, Luis Guillermo;
Zuluaga Salazar, Andrés Felipe;
Buendia, Jefferson Antonio

Publication type:

Article